Published May 2020
The AAOS Musculoskeletal Tumor Registry (MsTR) year-long pilot program was successful, and the AAOS Registry Program is excited to announce that new sites can enroll. The MsTR, an AAOS Registry with support from the Musculoskeletal Tumor Society (MSTS), has potential to fill a gap in current sarcoma care by focusing on quality-of-life and functional outcomes at a scale not previously attempted.
This is AAOS’ first diagnosis-based registry, as the other AAOS registries are procedure-based. The MsTR now allows surgeons to combine data about rare bone and soft tissue tumors from sites around the country, thereby potentially answering treatment and outcome questions that are otherwise unable to be answered due to the rarity of the disease.
Six pilot registry sites helped determine the most efficient, simplest, and most accurate methods to obtain high-yield data with appropriate statistical power that can drive future patient care. The MsTR pilot sites included:
- Cleveland Clinic Foundation
- Dartmouth-Hitchcock Medical Center
- Johns Hopkins Medicine
- Ohio State University-The James Cancer Hospital
- Stanford Health Care-Stanford Hospital
- University of Iowa Hospital and Clinics
MsTR feedback and dashboards will help clinicians and health systems track function, complications, and outcomes in patients treated for these sarcomas with the potential to expand to other musculoskeletal tumors and metastatic bone diseases in the future.
A Steering Committee has been formed to oversee the MsTR’s activities and growth. View the AAOS surgeon leaders that sit on the MsTR Steering Committee and an overview of MsTR data elements here.
“Sarcoma is a rare disease,” said Benjamin J. Miller, MD, FAAOS, MS, MsTR Steering Committee Chair. “More observations will lead to more results and data-driven conclusions that will change our practice for the better. This registry will allow for feedback to contributing [professionals] and centers through dashboards and periodic comparisons to national and personal quality and patient safety benchmarks that will be helpful not just to the clinicians but to their health systems. Registry participation is increasingly viewed as an option, perhaps an expectation, to be considered a high-quality institution. We believe that orthopaedic oncologists can make the case that participation in the Registry is as good for the institution as it is for the surgeons themselves. This will be a fee-based service to ensure sustainability and functionality over time; however, MSTS and AAOS agree that it is important to be as inclusive as possible. Any and all sarcoma centers interested in participating are encouraged to contact the MsTR team at the AAOS Registry Program to gather more information and start the enrollment process.”
If you are interested in enrolling your site in the MsTR, please contact AAOS Registry Engagement at RegistryEngagement@aaos.org.